Beyond Eligibility: Making Trust and Behavioral Readiness Actionable in Clinical Trial Recruitment

Eligibility criteria are fundamental to study design. They define who can take part. However, clinical eligibility alone is a poor predictor of whether a patient will decide to enroll.

Interviews with eligible individuals, who either enrolled in or declined a clinical trial, capture how decisions consistently transcended clinical checklists.¹ Even when a patient met every medical requirement, their ultimate choice routinely came down to three deeply human factors:

• Trust: In the investigators, institutions, and underlying motives behind the research.
• Hope: For personal clinical benefit or broader societal advancement.
• Fear: Of health degradation, systemic exploitation, or being treated merely as an anonymized data point.

Without trusted intermediaries to anchor the relationship, fear pulls harder; with them, hope gains momentum.

While logistical mitigations—such as covering travel costs, shortening visit windows, and simplifying consent forms—are critical to reducing participant burden, they are incomplete enablers.² They do not address these deeper behavioral drivers. As one eligible but hesitant interviewee noted: “I was just too scared.”

Why logic and education fall short

Recruitment strategies often default to education: factsheets, FAQs, safety statistics. These support cognitive trust—the rational case for participating—but they do little to build affective trust, the relational confidence that comes from emotional connection and lived experience.

Standard industry outreach is often transactional, short-lived, and tied strictly to rigid trial timelines. Sponsors fund brief awareness campaigns or blast promotional digital clinical trial portals, but they rarely invest the time required to build and sustain genuine community infrastructure. Raising awareness via ad-hoc community events or putting 'a face to a name' is a commendable start, but without long-term consistency, these efforts fall flat.

Furthermore, trial readiness is rarely created by the patient alone. It is often mediated by family members, clinicians, pharmacists, advocacy groups, faith leaders, and community organizations who help interpret whether a trial invitation is credible, safe, and worth considering. For sponsors and CROs, the practical question is therefore not only what message to deliver, but who has the relational authority to deliver or reinforce it.

The structural blind spot

There is a deeper reason conventional outreach struggles to reach the communities that trials most need. The data infrastructure underlying modern recruitment—electronic health records, claims databases, registries, and the AI tools built on them is a record of healthcare access and utilization, not true population health. Individuals facing systemic socioeconomic barriers or deep-seated institutional mistrust generate little to no clinical records, rendering them statistically invisible to traditional recruitment algorithms.

We call this the access-visibility gap, and it matters for a practical reason: the very individuals whose trust most needs to be earned are frequently invisible to the systems sponsors use to find participants. No algorithmic correction applied downstream can compensate for a population that was never captured upstream.

Making trust operational

For decades, behavioral readiness and trust have been difficult to operationalize. However, using advanced analytical frameworks, these signals can be empirically measured, validated, and scaled.

Platforms, such as Acclinate’s NOWINCLUDED, have been developed to capture where communities are already primed for engagement—the behavioral and attitudinal signals that surface through sustained relationships with churches, HBCUs, advocacy groups, and trusted local organizations. Engagement in these settings correlates with readiness to consider research in ways that clinical records cannot reveal. Aggregated, these signals let sponsors identify “community activation points”: where trust is already growing, which channels carry credibility, and where relational support will be needed before a logistical fix makes any difference.

The shift this enables is from broad, untargeted outreach—which posts low response rates precisely because it cannot distinguish the participation-ready from the participation-resistant—toward outreach matched to a community’s actual trust profile. A sponsor or CRO can tailor not just the message but the messenger and the channel. Crucially, analytics of this kind must be designed with safeguards against bias so they enhance equity rather than entrench it; the goal is to bring overlooked communities within reach, never to surveil or pressure them.

Translating lessons into practice

In practice, this requires a structured way to assess the trial pathway from the participant perspective, not only the protocol or site workflow. Engage Intelligently applies this approach by combining behavioral science with public and participant insights and real-time recruitment and retention monitoring data to identify where participation may feel difficult, unsafe, irrelevant, or unsupported, and where targeted changes are most likely to improve engagement.

Sponsors and CROs can implement three immediate structural changes to transition from reactive outreach to proactive, relationship-based engagement:

1. Embed behavioral readiness into feasibility

• Include short screeners on trust, support, and readiness alongside clinical eligibility.
• Stratify outreach pathways based on these predictive readiness scores, ensuring resource-intensive, high-touch relational tactics are directed toward demographics that require deeper validation.

2. Invest in relationship-based community engagement

• Allocate clinical budgets to sustain an authentic, non-transactional presence in local communities through trusted mediators, health partnerships, localized events, and advocacy networks.
• Shift operational performance metrics to track long-term trust indicators rather than focusing solely on immediate enrollment speed.

3. Train clinical site teams in behavioral drivers

• Integrate dedicated training modules covering the emotional dimensions of patient decision-making (trust, hope, and fear) into clinical research coordinator onboarding workflows.
• Reward teams for participant experience, not just enrollment numbers.

Guardrails for ethical and fair data use

Transitioning to predictive behavioral analytics requires robust data governance and compliance guardrails to ensure inclusivity without enabling predatory targeting or exploitation.

• Prioritize Aggregate Insights: Sponsors and CROs must prioritize aggregate community-level mapping over individual surveillance to identify localized 'activation points' that can be leveraged safely and effectively.
• Enforce Algorithmic Stewardship: Because trust and behavioral profiles are highly concentrated and culturally specific, models trained on a particular demographic cannot be generalized to other groups. Frameworks must be transparent, continuously audited, and statistically recalibrated when entering new geographic or cultural cohorts.
• Implement Community-Controlled Governance: To respect data sovereignty, data architectures should deploy decentralized, trust-based consent models that grant participants explicit control over how their insights are managed and shared with commercial clinical research entities.
• Maintain Strict Regulatory Compliance: Technology deployments must natively enforce rigorous data boundaries, ensuring full alignment with international frameworks like GDPR and HIPAA.

Call to action

To build a truly representative clinical research ecosystem, recruitment strategies must evolve from a purely static model of clinical eligibility to a dynamic understanding of human behavior. Sponsors and CROs must actively pair deep, localized community relationships with precision predictive analytics.

The message for sponsors and CROs is clear: eligibility is necessary, but behavior drives engagement—and behavior can now be understood, measured, and acted on.

About the authors

Cherish Boxall works at the intersection of behavioral science and clinical trial delivery, specializing in participant recruitment, retention, and representation. She is a Doctoral Fellow at the University of Southampton, UK, and Founder of Engage Intelligently, a participant engagement consultancy helping research teams turn evidence and behavioral insight into practical strategies for more inclusive trials.

Del Smith, PhD, works at the intersection of organizational behavior and technology. He is the Co-Founder and CEO of Acclinate, a US-based health-tech company focused on increasing representation in clinical trials.

References

1. Olszewski D, Tomaszewska A, Samolinski B. Factors influencing patients’ decisions regarding participation in clinical trials: review of current literature. Adv Clin Exp Med. 2025;34(6):1053–1064. doi:10.17219/acem/190453.
2. Nipp RD, Hong K, Paskett ED. Overcoming barriers to clinical trial enrollment. Am Soc Clin Oncol Educ Book. 2019;39:105–114. doi:10.1200/EDBK_243729.